Compare SPCB & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | OTLK |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 38.7M |
| IPO Year | N/A | 2016 |
| Metric | SPCB | OTLK |
|---|---|---|
| Price | $10.59 | $0.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 120.5K | ★ 12.5M |
| Earning Date | 11-13-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $26,739,000.00 | $1,413,535.00 |
| Revenue This Year | N/A | $1,578.49 |
| Revenue Next Year | $27.13 | $153.58 |
| P/E Ratio | $11.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.06 | $0.45 |
| 52 Week High | $14.00 | $3.39 |
| Indicator | SPCB | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 63.72 | 23.19 |
| Support Level | $8.16 | $0.51 |
| Resistance Level | $9.15 | $0.54 |
| Average True Range (ATR) | 0.66 | 0.04 |
| MACD | 0.23 | 0.03 |
| Stochastic Oscillator | 79.87 | 13.24 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.